Ketamine Versus Dexmedetomidine in Supraclavicular Brachial Plexus Block

• Status: Recruiting
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Intervention model description: The patients were randomly classified into three groups using computer-generated table numbers each contain (25) patients.

Ketamine group (group K): 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline plus 1 mg\kg ketamine, Dexmedetomidine group (group D): 20 ml 0.5% bupivacaine and 20 ml 0.9% normal saline plus 1µg\kg dexmedetomidine Control group (group C): 20 ml 0.5%bupivacaine and 20 ml 0.9% normal saline. Masking: double-blind (participant and investigator) Masking Description: The investigator's study is a prospective, randomized, double-blind

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Minia University
• Treatments: Bupivacaine; Dexmedetomidine; Ketamine

Criteria

Inclusion Criteria:

• American Physical Status I or II

• patients undergoing elective and emergency forearm and hand surgeries

Exclusion Criteria:

• Patient with bleeding disorders

• Damage or disease of the brachial plexus

• Uncontrolled diabetes mellitus

• Patients with neuromuscular diseases

• Patients with a local skin infection at the site of injection

• Patients with known hypersensitivity to studied drugs